Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn, Shukui Qin, Masafumi Ikeda, +17

New England Journal of Medicine

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Ann‐Lii Cheng, Shukui Qin, Masafumi Ikeda, +15

Journal of Hepatology

HepatologyAtezolizumab Plus BevacizumabUnresectable Hepatocellular CarcinomaMedicineImmunology +7

Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

Sae‐Won Han, Tae‐You Kim, Pil Gyu Hwang, +13

Journal of Clinical Oncology

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle, +200

The Lancet Oncology

OncologyHepatologyMedicineClinical TrialsPembrolizumab Versus Lenvatinib +8

IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).

Richard S. Finn, Shukui Qin, Masafumi Ikeda, +14

Journal of Clinical Oncology

ImmunodeficienciesClinical EndpointPathologyMultimodalityPharmacotherapy +20

Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis

Thomas Yau, Chiun Hsu, Tae‐You Kim, +14

Journal of Hepatology

Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation

Sae‐Won Han, Tae‐You Kim, Yoon Kyung Jeon, +9

Clinical Cancer Research

Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index

Younak Choi, Do‐Youn Oh, Tae‐Yong Kim, +5

PLoS ONE

Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis

Bhumsuk Keam, Seock‐Ah Im, Kyung-Hun Lee, +11

Breast Cancer Research

Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.

Thomas Yau, Yoon‐Koo Kang, Tae‐You Kim, +17

Journal of Clinical Oncology

PharmacotherapyNivo MonotherapyPre-clinical PharmacologyOncologyObjective Response Rate +17